€38.00
2.70% yesterday
Xetra, Dec 04, 05:35 pm CET
ISIN
DE000A2GS5D8
Symbol
DMP
Index

Dermapharm Stock price

€38.00
+5.00 15.15% 1M
+2.90 8.26% 6M
-0.90 2.31% YTD
+1.45 3.97% 1Y
-3.26 7.90% 3Y
-15.80 29.37% 5Y
+12.00 46.15% 10Y
+12.00 46.15% 20Y
Xetra, Closing price Thu, Dec 04 2025
+1.00 2.70%
ISIN
DE000A2GS5D8
Symbol
DMP
Index
Industry

New AI Insights on Dermapharm Insights AI Insights on Dermapharm

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
€2.0b
Enterprise Value
€2.9b
Net debt
€861.0m
Cash
€149.9m
Shares outstanding
53.8m
Valuation (TTM | estimate)
P/E
17.2 | 16.0
P/S
1.7 | 1.7
EV/Sales
2.5 | 2.4
EV/FCF
17.4
P/B
3.1
Dividends
DPS
€0.90
Yield 1Y | 5Y
2.4% | 2.4%
Growth 1Y | 5Y
2.3% | 2.4%
Payout 1Y | 3Y
42.7% | 49.1%
Increased
1 Year
Financials (TTM | estimate)
Revenue
€1.2b | €1.2b
EBITDA
€304.5m | €330.1m
EBIT
€217.0m | €236.7m
Net Income
€116.0m | €124.4m
Free Cash Flow
€164.4m
Growth (TTM | estimate)
Revenue
0.1% | 0.8%
EBITDA
-0.1% | 7.9%
EBIT
5.3% | 3.9%
Net Income
28.1% | 9.4%
Free Cash Flow
4.7%
Margin (TTM | estimate)
Gross
66.6%
EBITDA
26.3% | 27.7%
EBIT
18.7%
Net
10.0% | 10.5%
Free Cash Flow
14.2%
Financial Health
Equity Ratio
29.1%
Return on Equity
18.8%
ROCE
11.9%
ROIC
8.2%
Debt/Equity
1.6
More
EPS
€2.2
FCF per Share
€3.1
Short interest
-
Employees
4k
Rev per Employee
€330.0k
Show more

Is Dermapharm a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Dermapharm Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Dermapharm forecast:

8x Buy
73%
3x Hold
27%

Analyst Opinions

11 Analysts have issued a Dermapharm forecast:

Buy
73%
Hold
27%

Financial data from Dermapharm

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
1,160 1,160
0% 0%
100%
- Direct Costs 388 388
5% 5%
33%
772 772
3% 3%
67%
- Selling and Administrative Expenses 290 290
5% 5%
25%
- Research and Development Expense - -
-
-
305 305
0% 0%
26%
- Depreciation and Amortization 88 88
11% 11%
8%
EBIT (Operating Income) EBIT 217 217
5% 5%
19%
Net Profit 116 116
28% 28%
10%

In millions EUR.

Don't miss a Thing! We will send you all news about Dermapharm directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Dermapharm Stock News

AD HOC NEWS
about one month ago
Dermapharm Holding SE / DE000A2GS5D8
AD HOC NEWS
about one month ago
Aktienkäufe des Großaktionärs und Aufsichtsratschefs Wilhelm Beier haben am Montag Schwung in den Kurs der Dermapharm DE000A2GS5D8-Aktie gebracht.
More Dermapharm News

Company Profile

Dermapharm Holding SE engages in the development, manufacture. and market of patent-free pharmaceutical products. The company also involves in in-house development, in-house production, and distribution of pharmaceuticals and other healthcare products. It offers its products through the following brands: Dekristol 20,000 I.E., bite away, Herpotherm, sikapur, Ampho-Moronal, Solacutan, Ciclocutan, Minoxicutan, Prednisolut, Dienovel, Lactofem, Finapil, Panthenol-Augensalbe JENAPHARM, and Suxilep. The company was founded in 1991 and is headquartered in Grunwald, Germany.

Head office Germany
CEO Hans-Georg Feldmeier
Employees 3,610
Founded 1991
Website ir.dermapharm.de

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today